ESMO In Brief: PD-1 Updates, Perjeta’s Striking Survival, Boehringer’s Gilotrif Head-to-Head EGFR Data & More
This article was originally published in The Pink Sheet Daily
Executive Summary
Data for Merck’s Keytruda in bladder cancer and AstraZeneca’s CTLA-4/PD-L1 combo were among the immunotherapy updates at the 2014 ESMO meeting. Other notable releases include Perjeta’s striking survival data, a possible reprieve in lung for Endocyte’s vintafolide and head-to-head lung cancer data for Boehringer’s afatinib.
You may also be interested in...
Keeping Track: Venclexta Approved; Opdivo, Atezolizumab Seek Additional Indications
The latest drug development news and highlights from our FDA Performance Tracker.
Head-To-Head Lung Data Support Boehringer’s Gilotrif Over Iressa
Final results from the LUX-Lung 7 trial suggest superior efficacy for Boehringer’s EGFR inhibitor Gilotrif vs. AstraZeneca’s Iressa, albeit with a small absolute improvement in progression-free survival and a higher rate of severe diarrhea.
Roche Defends HER2 Franchise After MARIANNE Failure
MARIANNE frontline breast cancer trial failure was a blow, but HER2 franchise remains strong overall, particularly with the survival results from the CLEOPATRA study and other key studies due to report, company argues.